Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Estrogen Receptor Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT02376985
What this trial is testing

Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCT

Who this might be right for
Breast Cancer
Comprehensive Support Project for Oncology Research 174
Testing effectiveness (Phase 2)Study completedNCT04072952
What this trial is testing

A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Arvinas Estrogen Receptor, Inc. 217
Not applicableUnknownNCT02627703
What this trial is testing

(Oncotype DX®) in Estrogen Receptor Positive (ER+) HER-2 Negative (HER 2-) 1-3 Node Positive (pN1) Breast Cancer

Who this might be right for
Breast Cancer
British Columbia Cancer Agency 80
Not applicableStudy completedNCT00896727
What this trial is testing

S9313A Protein Expression Analysis of Breast Cancer Tissue Microarrays From Clinical Trial SWOG-9313

Who this might be right for
Breast Cancer
SWOG Cancer Research Network 2,100
Testing effectiveness (Phase 2)Ended earlyNCT02907918
What this trial is testing

Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer

Who this might be right for
Breast CancerCancer of BreastBreast Carcinoma
Washington University School of Medicine 26
Large-scale testing (Phase 3)Ended earlyNCT01303679
What this trial is testing

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

Who this might be right for
First Line Metastatic Breast Cancer
ARCAGY/ GINECO GROUP 117
Early research (Phase 1)Study completedNCT05501769
What this trial is testing

ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer

Who this might be right for
Breast Cancer
Arvinas Estrogen Receptor, Inc. 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT06206837
What this trial is testing

Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.

Who this might be right for
Breast Cancer
Pfizer 71
Post-approval studies (Phase 4)Study completedNCT05631795
What this trial is testing

Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 40
Testing effectiveness (Phase 2)Study completedNCT02188745
What this trial is testing

ER Reactivation Therapy for Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Dartmouth-Hitchcock Medical Center 20
Not applicableLooking for participantsNCT07563595
What this trial is testing

Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
iOMEDICO AG 500
Testing effectiveness (Phase 2)WithdrawnNCT01361945
What this trial is testing

AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast CancerHER-2 Positive Breast Cancer+1 more
Texas Tech University Health Sciences Center, El Paso
Very early researchStudy completedNCT03132467
What this trial is testing

Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer

Who this might be right for
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8+14 more
M.D. Anderson Cancer Center 16
Not applicableLooking for participantsNCT05541367
What this trial is testing

Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer

Who this might be right for
Breast CancerTNBC - Triple-Negative Breast CancerEstrogen-receptor-negative Breast Cancer
Tongji Hospital 80
Large-scale testing (Phase 3)Active Not RecruitingNCT06760637
What this trial is testing

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

Who this might be right for
Breast Cancer
Pfizer 1,035
Testing effectiveness (Phase 2)Study completedNCT02229084
What this trial is testing

Vaccination of High Risk Breast Cancer Patients

Who this might be right for
Breast CancerBreast Neoplasms
University of Arkansas 58
Early research (Phase 1)Ended earlyNCT07214662
What this trial is testing

Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

Who this might be right for
Breast Cancer
Genentech, Inc. 3
Testing effectiveness (Phase 2)UnknownNCT03202862
What this trial is testing

The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Fudan University 50
Not applicableStudy completedNCT02753686
What this trial is testing

Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy

Who this might be right for
HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer
Novartis Pharmaceuticals 440
Testing effectiveness (Phase 2)Study completedNCT01625286
What this trial is testing

Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients

Who this might be right for
Advanced or Metastatic Breast CancerER+ve Advanced or Metastatic Breast Cancer
AstraZeneca 148
Next Page